MILL VALLEY, Calif., March 31 /PRNewswire/ -- BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc. (www.us.biohit.com). Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, Biohit Inc. will cross-promote BioCision's highly thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes.
"BioCision's CoolRacks allow for the standardized cooling, freezing and thawing of samples stored in easy to open ErgoTubes," said Michelle Nemits, vice president of sales and business development for BioCision. "This co-promotion agreement allows BioCision to offer scientists the perfect combination of products that have been optimally designed for bench-top sample handling and improved productivity."
"The complementary nature of ErgoTubes and CoolRacks makes them ideal for cross-marketing," said Richard Miceli, Director of Sales & Marketing for Biohit Inc.. "We are pleased to be entering into this partnership with BioCision to co-promote our company's products, and we look forward to opportunities to expand this partnership in the future to include other product lines."
Biohit Inc. is a wholly-owned subsidiary of Biohit Oyj (www.biohit.com), a Helsinki, Finland- based company that develops, manufactures and markets liquid handling and diagnostic products for use in research, health care and industrial laboratories. Biohit has a worldwide network of 450 distributors, including 7 subsidiaries, in 70 countries. Please note the collaboration described herein is between Biohit Inc and BioCision LLC only.
BioCision is the leading maker of portable benchtop tools for temperature- sensitive biomedical samples and experiments. Its highly thermo-conductive CoolRack enables easy standardization of sample cooling, snap freezing, heating and thawing. Along with CoolRacks, BioCision's portable sample coolers, freezers, and thermally conductive platforms bring portability and all-day temperature control to drug discovery, and basic and clinical research, increasing reproducibility and accuracy in scientific experiments.
BioCision products have been adopted by leading pharmaceutical and biotechnology companies, contract research organizations, and academic and healthcare institutions worldwide. BioCision's customers include Amgen Inc., CDC, Harvard University, Genentech Inc., NIH, Novartis AG, Medimmune, Merck & Co. Inc., Pfizer Inc., Stanford University, and The Systems Biology Institute, among many others.
ABOUT BIOHIT
Biohit develops, manufactures and markets liquid handling products and accessories as well as diagnostic test systems for use in research, health care and industrial laboratories. Biohit's liquid handling business includes mechanical and electronic pipettes as well as disposable tips. In addition, Biohit offers maintenance, repair, and calibration services related to these products. In the diagnostics business, Biohit focuses on products and analysis systems for the screening, prevention and diagnosis of diseases of the gastrointestinal tract. Biohit operates all over the world. Production plants are located in Finland (Kajaani and Helsinki) and China (Suzhou). Subsidiaries are located in France, Germany, China, Japan, Russia, India, the U.K. and the U.S. Biohit's B-shares (BIOBV) have been quoted on NASDAQ OMX Helsinki since June 1999.
ABOUT BIOCISION
BioCision LLC, the CoolTech company, designs, manufactures and markets portable benchtop tools for all temperature-sensitive biomedical samples. BioCision's patent-pending CoolTech products enable researchers to achieve high pre-analytical sample reproducibility and consistency – experiment to experiment, lab to lab and clinical site to clinical site. The highly thermo-conductive CoolProducts, CoolRack and the complementary product lines CoolBox and CoolCell, are widely used by researchers in the pharmaceutical, biotechnology, academic and health care industries worldwide to ensure organized, protected and standardized sample handling. BioCision was founded in 2007 by a group of scientists, biomedical engineers and drug development experts. For more information, visit www.biocision.com.